Leukocyte-rich PRP or Leukocyte-free PRP vs Placebo in the Treatment of Epicondylitis: a Randomized Controlled Clinical Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug, Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The EPIC-PRP study is a double-blind randomized controlled clinical trial with 1:1:1 allocation.The objective of the study is to evaluate by means of a randomized controlled, double-blind clinical trial the clinical outcomes of echo-guided injection of PRP with or without leukocytes compared with echo-guided injection of saline for minimally invasive treatment of patients with epicondylitis resistant to conservative therapy. It will be the aim of the study to evaluate the efficacy and safety of the injection procedures by revealing the improvement and incidence of adverse events following treatment

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

‣ Patients with epicondylitis of the elbow:

• Patients with clinical picture of epicondylitis;

• Duration of symptoms \> 3 months

• Ultrasound picture of short or long radial extensor carpal tendinopathy;

• Age \> 18 and \< 65

• Both sexes;

• Failure, defined as persistence of symptoms, of other conservative treatments for at least 3 months;

• Hemoglobin \> 11 g/dl;

• Platelet count \> 150,000 plt/mm3 (Recently performed CBC examination);

• Negative serological tests for HBsAg, HCV Ab, HIV-1-2 Ab

⁃ No clinically significant electrocardiographic changes (Recently performed ECG);

⁃ Ability and consent of the patient to actively participate in clinical follow-up;

⁃ Signature of informed consent.

Locations
Other Locations
Italy
Istituto Ortopedico Rizzoli
RECRUITING
Bologna
Contact Information
Primary
Enrico Guerra, MD
enrico.guerra@ior.it
0516366567
Backup
Roberta Licciardi, MSc
roberta.licciardi@ior.it
6366567
Time Frame
Start Date: 2023-03-23
Estimated Completion Date: 2027-03
Participants
Target number of participants: 240
Treatments
Experimental: Leukocyte-rich Platelet rich plasma (LR-PRP)
This group of patients will be treated with single injection of autologous leukocyte rich platelet rich plasma.At the 6-month follow-up visit, the patient will be informed about the treatment received.
Experimental: Leukocyte-poor Platelet rich plasma (LP-PRP)
This group of patients will be treated withsSingle injection of autologous leukocyte poor platelet rich plasma.At the 6-month follow-up visit, the patient will be informed about the treatment received.
Placebo_comparator: Saline solution
This group of patients will be treated with single intra-articular injection of saline solution (placebo). At the 6-month follow-up visit, patients will be informed about the treatment received. Patients of this group can cross-over to the treatment arm after 6 months following a dedicated randomization list.
Related Therapeutic Areas
Sponsors
Leads: Istituto Ortopedico Rizzoli

This content was sourced from clinicaltrials.gov